Thermo Fisher Scientific Inc$577.11ETN · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $27.45B | $24.88B | $23.20B | $20.75B | $19.63B | $17.86B | $21.39B | $21.61B |
| Cost of Revenue | $17.13B | $15.38B | $14.76B | $13.87B | $13.29B | $12.41B | $14.34B | $14.51B |
| Research & Development | $797.00M | $794.00M | $754.00M | $665.00M | $616.00M | $551.00M | $606.00M | $584.00M |
| Selling, General & Administrative | $4.31B | $4.08B | $3.79B | $3.23B | $3.26B | $3.08B | $3.58B | $3.55B |
| Operating Income | — | — | — | — | — | — | $3.67B | $3.63B |
| Interest Expense | — | — | -$151.00M | -$144.00M | $144.00M | $149.00M | $199.00M | -$258.00M |
| Other Income / (Expense) | -$37.00M | $64.00M | $93.00M | $36.00M | -$40.00M | -$150.00M | -$73.00M | -$9.00M |
| Income Before Taxes | $4.93B | $4.57B | $3.83B | $2.91B | $2.90B | $1.75B | $2.59B | $2.42B |
| Provision for Income Taxes | $841.00M | $768.00M | $604.00M | $445.00M | $750.00M | $331.00M | $378.00M | $278.00M |
| Net Income | $4.09B | $3.79B | $3.22B | $2.46B | $2.14B | $1.41B | $2.21B | $2.15B |
| Basic EPS | $10.48 | $9.54 | $8.06 | $6.17 | $5.38 | $3.51 | $5.28 | $4.93 |
| Diluted EPS | $10.45 | $9.50 | $8.02 | $6.14 | $5.34 | $3.49 | $5.25 | $4.91 |
| Basic Shares Outstanding | 389.90M | 397.60M | 399.10M | 398.70M | 398.70M | 402.20M | 419.00M | 434.30M |
| Diluted Shares Outstanding | 391.20M | 399.40M | 401.10M | 400.80M | 401.60M | 404.00M | 420.80M | 436.90M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $13.53 | $13.43 | $13.60 | 6 | ↑5 ↓0 |
| Dec 2027 | $15.80 | $14.68 | $16.37 | 12 | ↑5 ↓0 |
| Dec 2028 | $18.33 | $16.92 | $19.89 | 5 | ↑3 ↓0 |
| Dec 2029 | $21.80 | $19.43 | $24.16 | 2 | ↑2 ↓0 |
